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NO ELECTROMAGNETIC INTERFERENCE EXISTS BETWEEN THE
NEW REMOTE MONITORING SYSTEM AND IMPLANTABLE DEVICES
Hai JJ , Horgan AL, Friedman PA, Bruce CJ, Asirvatham SJ, Hayes DL. Division of Cardiovascular
Diseases, Mayo Clinic, Rochester, MN, USA.
Introduction: The BodyGuardian® is a novel remote monitoring platform comprised of a rechargeable
module that attaches to an adhesive patch with attached electrodes. ECG, respiration, activity level and
other clinical parameters are transmitted via Bluetooth to a smartphone and then to the central cloud
platform via cellular or Wi-Fi connection for clinical review (Figure). Although approved for clinical
use, potential electromagnetic interference (EMI) precludes its use among patients with implantable
devices.
Method: We prospectively recruited 100 patients with permanent pacemaker (PPM) or implantable
cardioverter defibrillator (ICD) who were followed in our institution. The patient was monitored during
acquisition and transmission of electrocardiogram using the BodyGuardian® remote monitoring system
while the implantable device was programed to usual and maximal sensitivities and observed for EMI.
Results: Of the 100 patients recruited, a single chamber ICD was implanted in 47, dual chamber ICD in
5, single chamber ventricular PPM in 21, atrial PPM in 1, dual chamber PPM in 26, and the
rate-responsive mode was turned on in 44. The mean permanently programmed sensitivity was
0.51±0.64mV for the atrial lead and 1.72±1.88mV for the ventricular lead, and the maximal sensitivity
was 0.06±0.09mV for the atrial lead and 0.25±0.35mV for the ventricular lead. The BodyGuardian®
module and adhesive electrode strip was applied to the skin, directly over the implanted device in all
cases. In 208 successful acquisitions and transmissions of electrocardiogram as verified on the cloud
platform, no EMI was detected.  
Conclusion: No EMI was detected with PPM or ICD during the use of the BodyGuardian® remote
monitoring system. This new system can be safely used in patients with implantable devices or by
patients that are in close physical contact with others with implantable cardiac devices. 
